Does the media prefer IRON or BMRN?

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than Disc Medicine. MarketBeat recorded 25 mentions for BioMarin Pharmaceutical and 18 mentions for Disc Medicine. BioMarin Pharmaceutical's average media sentiment score of 0.77 beat Disc Medicine's score of 0.56 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 7 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IRON or MDGL?

In the previous week, Disc Medicine had 10 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 18 mentions for Disc Medicine and 8 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.37 beat Disc Medicine's score of 0.56 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, IRON or SMMT?

Disc Medicine is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is IRON or SMMT more profitable?

Disc Medicine's return on equity of -37.17% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Summit Therapeutics N/A -168.94% -141.92%

Does the media refer more to IRON or SMMT?

In the previous week, Disc Medicine had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 18 mentions for Disc Medicine and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.76 beat Disc Medicine's score of 0.56 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ABVX or IRON?

Abivax is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Disc Medicine N/A N/A -$212.18M -$6.58 N/A

Is ABVX or IRON more profitable?

Disc Medicine's return on equity of -37.17% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Disc Medicine N/A -37.17% -33.65%

Does the media prefer ABVX or IRON?

In the previous week, Disc Medicine had 16 more articles in the media than Abivax. MarketBeat recorded 18 mentions for Disc Medicine and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Disc Medicine's score of 0.56 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Disc Medicine 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HALO or IRON?

In the previous week, Halozyme Therapeutics had 9 more articles in the media than Disc Medicine. MarketBeat recorded 27 mentions for Halozyme Therapeutics and 18 mentions for Disc Medicine. Halozyme Therapeutics' average media sentiment score of 0.76 beat Disc Medicine's score of 0.56 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 8 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Disc Medicine (IRON) Competitors

$78.80 -1.21 (-1.51%)

As of 10:43 AM Eastern

Compare

IRON vs. BMRN, MDGL, SMMT, ABVX, and HALO

Should you buy Disc Medicine stock or one of its competitors? Disc Medicine's main competitors and comparable companies include BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Summit Therapeutics (SMMT), Abivax (ABVX), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Disc Medicine compare to BioMarin Pharmaceutical?

Disc Medicine (NASDAQ:IRON) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Disc Medicine has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Disc Medicine's net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Disc Medicine currently has a consensus price target of $106.00, suggesting a potential upside of 34.52%. BioMarin Pharmaceutical has a consensus price target of $88.00, suggesting a potential upside of 30.76%. Given Disc Medicine's stronger consensus rating and higher probable upside, research analysts clearly believe Disc Medicine is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

In the previous week, BioMarin Pharmaceutical had 7 more articles in the media than Disc Medicine. MarketBeat recorded 25 mentions for BioMarin Pharmaceutical and 18 mentions for Disc Medicine. BioMarin Pharmaceutical's average media sentiment score of 0.77 beat Disc Medicine's score of 0.56 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	7 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
BioMarin Pharmaceutical	$3.22B	4.04	$348.90M	$0.37	181.89

Summary

BioMarin Pharmaceutical beats Disc Medicine on 12 of the 16 factors compared between the two stocks.

How does Disc Medicine compare to Madrigal Pharmaceuticals?

Disc Medicine (NASDAQ:IRON) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Disc Medicine presently has a consensus price target of $106.00, suggesting a potential upside of 34.52%. Madrigal Pharmaceuticals has a consensus price target of $689.93, suggesting a potential upside of 37.71%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Disc Medicine has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, meaning that its share price is 201% less volatile than the broader market.

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Disc Medicine has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Madrigal Pharmaceuticals	$958.40M	12.08	-$288.28M	-$12.89	N/A

Disc Medicine has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Disc Medicine's return on equity of -37.17% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

In the previous week, Disc Medicine had 10 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 18 mentions for Disc Medicine and 8 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.37 beat Disc Medicine's score of 0.56 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Madrigal Pharmaceuticals beats Disc Medicine on 8 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Summit Therapeutics?

Disc Medicine (NASDAQ:IRON) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Disc Medicine is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Disc Medicine had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 18 mentions for Disc Medicine and 9 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.76 beat Disc Medicine's score of 0.56 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Disc Medicine presently has a consensus price target of $106.00, suggesting a potential upside of 34.52%. Summit Therapeutics has a consensus price target of $24.25, suggesting a potential upside of 82.98%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

Disc Medicine has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Summit Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market.

Disc Medicine's return on equity of -37.17% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summary

Disc Medicine beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Disc Medicine compare to Abivax?

Abivax (NASDAQ:ABVX) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Abivax is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

In the previous week, Disc Medicine had 16 more articles in the media than Abivax. MarketBeat recorded 18 mentions for Disc Medicine and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Disc Medicine's score of 0.56 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Disc Medicine	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Disc Medicine's return on equity of -37.17% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Disc Medicine	N/A	-37.17%	-33.65%

47.9% of Abivax shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Abivax currently has a consensus price target of $156.50, indicating a potential upside of 29.65%. Disc Medicine has a consensus price target of $106.00, indicating a potential upside of 34.52%. Given Disc Medicine's higher possible upside, analysts plainly believe Disc Medicine is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Disc Medicine beats Abivax on 8 of the 13 factors compared between the two stocks.

How does Disc Medicine compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Halozyme Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	6.72	$316.89M	$3.35	29.42
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Halozyme Therapeutics presently has a consensus target price of $91.20, indicating a potential downside of 7.45%. Disc Medicine has a consensus target price of $106.00, indicating a potential upside of 34.52%. Given Disc Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Disc Medicine is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Halozyme Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Halozyme Therapeutics had 9 more articles in the media than Disc Medicine. MarketBeat recorded 27 mentions for Halozyme Therapeutics and 18 mentions for Disc Medicine. Halozyme Therapeutics' average media sentiment score of 0.76 beat Disc Medicine's score of 0.56 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	8 Very Positive mention(s)	7 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 24.86% compared to Disc Medicine's net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Disc Medicine	N/A	-37.17%	-33.65%

Summary

Halozyme Therapeutics beats Disc Medicine on 10 of the 15 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRON vs. The Competition

Export

Metric	Disc Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$301.80M	$3.69B	$6.96B	$13.10B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-11.98	10.23	269.57	25.32
Price / Sales	N/A	1,285.96	595.01	100.00
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	0.47	17.54	13.06	6.29
Net Income	-$212.18M	-$13.32M	$3.45B	$347.70M
7 Day Performance	1.76%	0.19%	0.47%	0.89%
1 Month Performance	5.05%	-0.03%	1.11%	0.85%
1 Year Performance	29.78%	53.11%	66.38%	20.25%

Disc Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRON Disc Medicine	2.621 of 5 stars	$78.80 -1.5%	$106.00 +34.5%	+30.9%	$301.80M	N/A	N/A	30
BMRN BioMarin Pharmaceutical	4.856 of 5 stars	$60.72 +1.2%	$88.26 +45.4%	+17.5%	$11.74B	$3.22B	44.32	3,221	Analyst Downgrade
MDGL Madrigal Pharmaceuticals	4.0484 of 5 stars	$507.56 +5.3%	$689.93 +35.9%	+35.9%	$11.72B	$958.40M	N/A	90	Positive News Gap Up
SMMT Summit Therapeutics	4.0593 of 5 stars	$13.76 +5.4%	$26.15 +90.1%	-47.9%	$10.98B	N/A	N/A	110	Analyst Upgrade
ABVX Abivax	2.4825 of 5 stars	$125.19 +0.3%	$156.50 +25.0%	+73.9%	$10.92B	N/A	N/A	61	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Disc Medicine (IRON) Competitors

IRON vs. BMRN, MDGL, SMMT, ABVX, and HALO

How does Disc Medicine compare to BioMarin Pharmaceutical?

Summary

How does Disc Medicine compare to Madrigal Pharmaceuticals?

Summary

How does Disc Medicine compare to Summit Therapeutics?

Summary

How does Disc Medicine compare to Abivax?

Summary

How does Disc Medicine compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Disc Medicine (IRON) Competitors

IRON vs. BMRN, MDGL, SMMT, ABVX, and HALO

How does Disc Medicine compare to BioMarin Pharmaceutical?

Which has more volatility and risk, IRON or BMRN?

Do insiders & institutionals hold more shares of IRON or BMRN?

Is IRON or BMRN more profitable?

Do analysts prefer IRON or BMRN?

Does the media prefer IRON or BMRN?

Which has preferable valuation & earnings, IRON or BMRN?

Summary

How does Disc Medicine compare to Madrigal Pharmaceuticals?

Do analysts rate IRON or MDGL?

Which has more risk & volatility, IRON or MDGL?

Do institutionals & insiders hold more shares of IRON or MDGL?

Which has stronger valuation & earnings, IRON or MDGL?

Is IRON or MDGL more profitable?

Does the media refer more to IRON or MDGL?

Summary

How does Disc Medicine compare to Summit Therapeutics?

Which has better earnings and valuation, IRON or SMMT?

Do institutionals & insiders have more ownership in IRON or SMMT?

Does the media refer more to IRON or SMMT?

Do analysts rate IRON or SMMT?

Which has more risk & volatility, IRON or SMMT?

Is IRON or SMMT more profitable?

Summary

How does Disc Medicine compare to Abivax?

Which has stronger earnings & valuation, ABVX or IRON?

Does the media prefer ABVX or IRON?

Is ABVX or IRON more profitable?

Do institutionals and insiders believe in ABVX or IRON?

Which has more risk & volatility, ABVX or IRON?

Do analysts prefer ABVX or IRON?

Summary

How does Disc Medicine compare to Halozyme Therapeutics?

Which has stronger valuation and earnings, HALO or IRON?

Do analysts rate HALO or IRON?

Which has more risk & volatility, HALO or IRON?

Do institutionals & insiders believe in HALO or IRON?

Does the media refer more to HALO or IRON?

Is HALO or IRON more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools